Undercarboxylated Osteocalcin: A Promising Target for Early Diagnosis of Cardiovascular and Glycemic Disorders in Patients with Metabolic Syndrome: A Pilot Study
Metadatos
Mostrar el registro completo del ítemAutor
Riquelme Gallego, Blanca; García Molina, Laura; Cano Ibáñez, Naomi; Andújar Vera, Francisco Luis; González Salvatierra, Sheila; García Fontana, Cristina; Bueno Cavanillas, Aurora; Muñoz Torres, Manuel Eduardo; García Fontana, BeatrizEditorial
MDPI
Materia
Metabolic syndrome Cardiovascular risk Diabetes Osteocalcin Mediterranean diet
Fecha
2022-07-21Referencia bibliográfica
Riquelme-Gallego, B... [et al.]. Undercarboxylated Osteocalcin: A Promising Target for Early Diagnosis of Cardiovascular and Glycemic Disorders in Patients with Metabolic Syndrome: A Pilot Study. Nutrients 2022, 14, 2991. [https://doi.org/10.3390/nu14142991]
Patrocinador
Instituto de Salud Carlos III European Commission PI18-00803 PI21/01069 PI18-01235 FI19/00118 CD20/00022; European Commission; Junta de Andalucia CD20/00022 PI-0268-2019 RH-00692021Resumen
Lifestyle changes are causing an exponential increase in the prevalence of obesity and
metabolic syndrome (MetS) worldwide. The most frequent complications of these are the development
of diabetes (T2D) and cardiovascular disease (CVD). Accurate tools are needed to classify the
cardiovascular risk (CVR) in the MetS population. In recent years, numerous biomarkers of bone
metabolism have been associated with CVR. The aim of this study was to determine the levels of
undercarboxylated osteocalcin (ucOC) in a cohort of patients with MetS and to analyse its association
with MetS parameters and CVR as well as with T2D prevalence. A longitudinal study was
conducted in which a MetS population was followed for one year. Weight change, adherence to the
Mediterranean diet (MedDiet), ucOC levels, MetS parameters and CVR were analysed and CVR was
calculated using different scores. Our results showed a decrease of CVR associated with a better
adherence to the MetDiet resulting in higher HDL-C and ucOC levels though the improvement of
MetS risk factors. This bone protein appeared as a potential biomarker to classify CVR in the MetS
population, especially for MetS patients without prevalent T2D. Furthermore, ucOC serum levels
could be good predictors of T2D prevalence.